

drug.

Fax completed form to: (855) 840-1678
If this is an URGENT request, please call (800) 882-4462 (800.88.CIGNA)

## Tremfya IV (guselkumab)

PHYSICIAN INFORMATION PATIENT INFORMATION \* Physician Name: \*Due to privacy regulations we will not be able to respond via fax with the outcome of our review unless all asterisked (\*) items on this Specialty: \* DEA, NPI or TIN: form are completed.\* \* Patient Name: Office Contact Person: \* Cigna ID: Office Phone: \* Date of Birth: \* Patient Street Address: Office Fax: Office Street Address: State: City: Zip: State: Patient Phone: City: Zip: **Urgency:** ☐ Standard Urgent (In checking this box, I attest to the fact that applying the standard review time frame may seriously jeopardize the customer's life, health, or ability to regain maximum function) **Medication requested:** ☐ Tremfya IV ICD10: Directions for use: Dose and Quantity: Duration of therapy: Where will this medication be obtained? ☐ Retail pharmacv ☐ Accredo Specialty Pharmacy\*\* ☐ Home Health / Home Infusion vendor ☐ Hospital Outpatient ☐ Prescriber's office stock (billing on a medical claim form) \*\*Cigna's nationally preferred specialty pharmacy Other (please specify): \*\*Medication orders can be placed with Accredo via E-prescribe - Accredo (1620 Century Center Pkwy, Memphis, TN 38134-8822 NCPDP 4436920), Fax 888.302.1028, or Verbal 866.759.1557 Facility and/or doctor dispensing and administering medication: Facility Name: State: Tax ID#: Address (City, State, Zip Code): Is the requested medication for a chronic or long-term condition for which the prescription medication may be necessary for the life of the patient? ☐ Yes ☐ No Diagnosis related to use: ☐ Crohn's disease Ulcerative colitis All other indications or diagnoses **Clinical Information:** Will the requested medication be administered in combination with a BIOLOGIC or in combination with a targeted synthetic oral small molecule drug? Biologic (an adalimumab product [Humira, biosimilar], Bimzelx, Cosentyx (IV or SC), etanercept SC product [Enbrel, biosimilar], Entyvio (IV or SC), Ilumya, infliximab IV products [Remicade, biosimilar], Kevzara, Kineret, Omvoh (IV or SC), Orencia [IV or SC], a rituximab IV product [Rituxan, biosimilar], Skyrizi (IV or SC), Siliq, Simponi [Aria or SC]), an ustekinumab product [Stelara (IV or SC), biosimilar], Taltz, a tocilizumab product [Actemra (IV or SC), biosimilar], Tremfya (IV or SC), or Zymfentra Targeted synthetic oral small molecule drug (such as Cibingo, Leqselvi, Litfulo, Sotyktu, Olumiant, Otezla, Rinvoq, Rinvoq LQ, Xeljanz, Xeljanz XR, Velsipity, or Zeposia.) ☐ Conventional synthetic DMARD (such as methotrexate, leflunomide, hydroxychloroquine, or sulfasalazine) ☐ No, the requested medication will NOT be used in combination with another BIOLOGIC or targeted synthetic oral small molecule

(if CD) Has the patient tried a systemic corticosteroid or is currently taking a systemic corticosteroid?	☐ Yes ☐ No
(if no) Is a systemic corticosteroid contraindicated in this patient?	☐ Yes ☐ No
(if no) Has the patient tried one other conventional systemic therapy for Crohn's disease? Please Note: Examples of systemic therapies for Crohn's disease include azathioprine, 6-mercaptopurine, and methotrexate. A trial of mesalamine does not count as a systemic agent for Crohn's disease.	
(if no) Has the patient had a previous trial of one biologic for Crohn's disease drug? Please Note: A biosimilar of the requested biologic does not count. Exa Cimzia, Entyvio, an infliximab IV product (Remicade, biosimilars), an adalimul biosimilars), Omvoh (IV or SC), Skyrizi (IV or SC), an ustekinumab product [S Zymfentra.	amples of biologics include mab product (Humira,
(if no) Does the patient have enterocutaneous (perianal or abdomina	ıl) or rectovaginal fistulas? ☐ Yes ☐ No
(if no) Has the patient had an ileocolonic resection (to reduce disease recurrence)?	
(if CD or UC) Will the requested medication be used as induction therapy?	☐ Yes ☐ No
(if CD or UC) Is this medication being prescribed by or in consultation with a gastroenterologist?	☐ Yes ☐ No
Additional Pertinent Information: Please provide any additional pertinent clinical information, including: if the patient is currently on the requested drug (with dates of use) and how they have been receiving it (for example: samples, out of pocket).	
Attestation: I attest the information provided is true and accurate to the best of my knowledge. I understand that the Health Plan or insurer its designees may perform a routine audit and request the medical information necessary to verify the accuracy of the information reported on this form.	
Prescriber Signature: Date	
Save Time! Submit Online at: <a href="https://www.covermymeds.com/main/prior-authorization-forms/cigna/">www.covermymeds.com/main/prior-authorization-forms/cigna/</a> or via SureScripts in your EHR.	
Our standard response time for prescription drug coverage requests is 5 business days. If your request is urgent, it is important that	

Our standard response time for prescription drug coverage requests is 5 business days. If your request is urgent, it is important that you call us to expedite the request. View our Prescription Drug List and Coverage Policies online at cigna.com.

v090125

"Cigna" is a registered service mark, and the "Tree of Life" logo is a service mark, of Cigna Intellectual Property, Inc., licensed for use by Cigna Corporation and its operating subsidiaries. All products and services are provided by or through such operating subsidiaries and not by Cigna Corporation. Such operating subsidiaries include, for example, Cigna Health and Life Insurance Company and Cigna Health Management, Inc. Address: Cigna Pharmacy Services, PO Box 42005, Phoenix AZ 85080-2005